Senzar Asset Management LLC Has $415,000 Stake in TG Therapeutics Inc common stock (TGTX)

Share on StockTwits

Senzar Asset Management LLC reduced its position in TG Therapeutics Inc common stock (NASDAQ:TGTX) by 93.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,594 shares of the biopharmaceutical company’s stock after selling 444,324 shares during the quarter. TG Therapeutics Inc common stock makes up about 1.2% of Senzar Asset Management LLC’s portfolio, making the stock its 20th largest position. Senzar Asset Management LLC’s holdings in TG Therapeutics Inc common stock were worth $415,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TGTX. venBio Select Advisor LLC boosted its stake in shares of TG Therapeutics Inc common stock by 58.7% in the 1st quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock valued at $74,261,000 after purchasing an additional 1,935,156 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of TG Therapeutics Inc common stock by 2,148.1% in the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock valued at $11,686,000 after purchasing an additional 849,233 shares during the last quarter. BlackRock Inc. boosted its stake in shares of TG Therapeutics Inc common stock by 17.4% in the 2nd quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock valued at $53,667,000 after purchasing an additional 605,844 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of TG Therapeutics Inc common stock in the 1st quarter valued at $8,574,000. Finally, Highland Capital Management LP bought a new stake in shares of TG Therapeutics Inc common stock in the 1st quarter valued at $6,595,000. 48.99% of the stock is currently owned by institutional investors.

TG Therapeutics Inc common stock stock opened at $12.40 on Wednesday. TG Therapeutics Inc common stock has a 12-month low of $7.25 and a 12-month high of $17.35. The firm has a market cap of $1.05 billion, a P/E ratio of -6.49 and a beta of 1.16.

TG Therapeutics Inc common stock (NASDAQ:TGTX) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). TG Therapeutics Inc common stock had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. research analysts expect that TG Therapeutics Inc common stock will post -2.19 earnings per share for the current fiscal year.

In related news, CFO Sean A. Power sold 47,191 shares of the business’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $13.21, for a total transaction of $623,393.11. Following the transaction, the chief financial officer now owns 473,267 shares in the company, valued at approximately $6,251,857.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William James Kennedy sold 25,071 shares of the business’s stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $13.45, for a total transaction of $337,204.95. The disclosure for this sale can be found here. 15.10% of the stock is owned by insiders.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research lowered shares of TG Therapeutics Inc common stock from a “hold” rating to a “sell” rating in a research note on Thursday, May 10th. ValuEngine raised shares of TG Therapeutics Inc common stock from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 5th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of TG Therapeutics Inc common stock in a research note on Tuesday, August 7th. Finally, BidaskClub raised shares of TG Therapeutics Inc common stock from a “sell” rating to a “hold” rating in a research note on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.00.

About TG Therapeutics Inc common stock

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Further Reading: Analyst Ratings

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc common stock (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics Inc common stock (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc common stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply